Cord blood therapy offers hope for long COVID sufferers

NCT ID NCT07332338

First seen Jan 12, 2026 · Last updated May 08, 2026 · Updated 17 times

Summary

This expanded access program offers REGENECYTE, a human umbilical cord blood infusion, to adults with Long COVID who are not eligible for other clinical trials. The goal is to manage ongoing symptoms like chronic fatigue. Participants must have a recent negative COVID-19 test and provide consent.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • D&H National Research Center #1

    AVAILABLE

    Miami, Florida, 33169, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Myrak Research Center Inc.

    AVAILABLE

    Miami Lakes, Florida, 33014, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.